Evidence map›Paper›PMID 41820948›Full record

ArticleBMC pulmonary medicine2026

Authentic neuroendocrine transdifferentiation from lung adenocarcinoma to small-cell lung cancer: a case report.

Mengqian Li, Ping Zhou, Xuexue Wu, Lili Jiang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mengqian Li *Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Ping Zhou *Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xuexue WuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lili JiangDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. jianglili@scu.edu.cn.

Funding

Young Scientists Fund of the National Natural Science Foundation of China 82504852
6 · The paper itself

Abstract

backgroundReports of small-cell lung cancer (SCLC) transdifferentiation in epidermal growth factor receptor tyrosine (EGFR)‑mutant lung adenocarcinoma (LUAD) often reflect pre‑existing combined SCLC or are limited by sampling bias, obscuring true treatment‑induced lineage transformation. CASE PRESENTATION: We report a female patient with EGFR‑mutant LUAD who, during EGFR tyrosine kinase inhibitor therapy, developed SCLC transformation confirmed histopathologically. The patient showed limited response to first‑line SCLC chemoimmunotherapy, and a subsequent biopsy revealed mixed SCLC/LUAD histology with neuroendocrine differentiation and shared genetic alterations between components.

conclusionsThis case provides strong clinicopathological and molecular evidence supporting neuroendocrine transdifferentiation from LUAD to SCLC, culminating in a mixed phenotypic state. Further research is needed to define optimal therapeutic strategies for this resistant phenotype.

Indexed as

Adenocarcinoma of LungCell TransdifferentiationLung NeoplasmsSmall Cell Lung CarcinomaErbB ReceptorsFemaleHumansMutationProtein Kinase InhibitorsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsCase reportEGFR-mutant lung adenocarcinomaLineage plasticityNeuroendocrine transdifferentiationSmall-cell lung cancer

Identifiers

PMID41820948
PMCPMC13093959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.